AR050255A1 - Composicion farmaceutica conteniendo fragmentos polipeptidicos de serralisinas - Google Patents

Composicion farmaceutica conteniendo fragmentos polipeptidicos de serralisinas

Info

Publication number
AR050255A1
AR050255A1 ARP050102834A ARP050102834A AR050255A1 AR 050255 A1 AR050255 A1 AR 050255A1 AR P050102834 A ARP050102834 A AR P050102834A AR P050102834 A ARP050102834 A AR P050102834A AR 050255 A1 AR050255 A1 AR 050255A1
Authority
AR
Argentina
Prior art keywords
composition
serralisine
pharmaceutical composition
composition containing
prodigiosins
Prior art date
Application number
ARP050102834A
Other languages
English (en)
Inventor
Perez Maria Del Car Abrahantes
Gonzalez Jesus Reyes
Rios Gloria Veliz
Marianao Eduardo Martinez
Gonzalez Caridad Anais Gasmuri
Suarez Jose Garcia
Lopez Luis Javier Gonzalez
Serra Lila Rosa Castellanos
Sosa Manuel Selman-Housein
Riera Raul Gomez
Cowley Jorge Victor Gavilondo
Romero Monica Bequet
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of AR050255A1 publication Critical patent/AR050255A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/265—Enterobacter (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente está relacionada con una composicion capaz de inhibir el crecimiento de células tumorales de diferentes orígenes histologicos y de células endoteliales activadas. Los componentes de dicha composicion son fragmentos polipéptidos de Serralisinas, correspondientes al fragmento C-terminal, a partir de la metionina interna de la secuencia hasta el final de la molécula, los cuales pueden combinarse entre ellos y opcionalmente con prodigiosinas que potencian el efecto anti-tumoral de la composicion. Las prodigiosinas en la composicion pueden estar a una concentracion de 0.1-100 nM. La accion anti-proliferativa de la composicion está mediada por mecanismos apoptoticos. Su administracion "in vivo" tiene efecto antitumoral, antiangiogénico y protector contra tumores malignos.
ARP050102834A 2004-07-08 2005-07-08 Composicion farmaceutica conteniendo fragmentos polipeptidicos de serralisinas AR050255A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20040147A CU23475A1 (es) 2004-07-08 2004-07-08 Composición farmacéutica conteniendo fragmentos polipeptídicos de serralisinas

Publications (1)

Publication Number Publication Date
AR050255A1 true AR050255A1 (es) 2006-10-11

Family

ID=40259088

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102834A AR050255A1 (es) 2004-07-08 2005-07-08 Composicion farmaceutica conteniendo fragmentos polipeptidicos de serralisinas

Country Status (22)

Country Link
US (1) US8076297B2 (es)
EP (1) EP1787653B1 (es)
JP (1) JP4914350B2 (es)
KR (1) KR101365056B1 (es)
AR (1) AR050255A1 (es)
AU (1) AU2005262159B2 (es)
BR (1) BRPI0513136A (es)
CA (1) CA2572984C (es)
CU (1) CU23475A1 (es)
CY (1) CY1114201T1 (es)
DK (1) DK1787653T3 (es)
ES (1) ES2389126T3 (es)
HR (1) HRP20120682T1 (es)
MX (1) MX2007000339A (es)
MY (1) MY150858A (es)
PL (1) PL1787653T3 (es)
PT (1) PT1787653E (es)
RS (1) RS52448B (es)
RU (1) RU2396274C2 (es)
SI (1) SI1787653T1 (es)
WO (1) WO2006005268A2 (es)
ZA (1) ZA200700178B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2378777T3 (es) * 2004-11-23 2012-04-17 Zymogenetics, Inc. Purificación del factor XIII humano recombinante
JP5296051B2 (ja) 2007-05-04 2013-09-25 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Ｍｒコイル吸収の補正を伴うハイブリッドｍｒ／ｐｅｔ
CU23950B1 (es) 2011-03-21 2013-10-29 Ct De Ingeniería Genética Y Biotecnología Péptidos cíclicos con actividad antineoplásica y antiangiogénica
TWI746449B (zh) * 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法
CN109295041A (zh) * 2018-10-10 2019-02-01 宁波希诺亚海洋生物科技有限公司 具有舍雷肽酶活性的多肽及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58134991A (ja) * 1981-12-28 1983-08-11 Takeda Chem Ind Ltd セラチオペプチタ−ゼの安定化法
JP2611206B2 (ja) * 1985-11-15 1997-05-21 武田薬品工業株式会社 遺伝子およびその利用方法
KR100252197B1 (ko) 1997-09-20 2000-04-15 박호군 세라시아 마르세센스 균주의 배양액으로 부터 분리한 면역억제제용 프로디지오신
US20040185566A1 (en) * 2003-03-19 2004-09-23 Peter Salamone Polypeptides toxic to nematodes and methods of use

Also Published As

Publication number Publication date
CU23475A1 (es) 2009-12-17
CY1114201T1 (el) 2016-08-31
DK1787653T3 (da) 2012-09-17
US8076297B2 (en) 2011-12-13
SI1787653T1 (sl) 2012-10-30
US20110218138A1 (en) 2011-09-08
ES2389126T3 (es) 2012-10-23
PT1787653E (pt) 2012-09-06
BRPI0513136A (pt) 2008-04-29
CA2572984C (en) 2014-12-09
EP1787653A2 (en) 2007-05-23
MX2007000339A (es) 2007-03-12
JP4914350B2 (ja) 2012-04-11
WO2006005268A2 (es) 2006-01-19
PL1787653T3 (pl) 2012-11-30
MY150858A (en) 2014-03-14
KR101365056B1 (ko) 2014-02-21
KR20070042542A (ko) 2007-04-23
AU2005262159A1 (en) 2006-01-19
RU2396274C2 (ru) 2010-08-10
RS52448B (en) 2013-02-28
WO2006005268A3 (es) 2006-03-09
HRP20120682T1 (hr) 2012-09-30
ZA200700178B (en) 2008-06-25
AU2005262159B2 (en) 2011-08-18
CA2572984A1 (en) 2006-01-19
RU2007104776A (ru) 2008-08-20
JP2008505129A (ja) 2008-02-21
EP1787653B1 (en) 2012-06-06

Similar Documents

Publication Publication Date Title
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
ATE535252T1 (de) Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit
AR053651A1 (es) Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama
BR0316050A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
AR050255A1 (es) Composicion farmaceutica conteniendo fragmentos polipeptidicos de serralisinas
EP3533461A3 (en) Prame derived peptides and immunogenic compositions comprising these
AR059982A1 (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
HK1101131A1 (en) Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
CL2008001813A1 (es) Compuestos derivados de quinolin-3-carbonitrilo sustituidos con piperazina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis, inflamacion, cancer entre otras (div. sol. 266-04).
ECSP056159A (es) Composición de fármaco conjugado
BRPI0516577A (pt) agentes terapêuticos com toxicidade diminuìda
BR112015009037A2 (pt) composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1
AR080891A1 (es) Proteina de fusion robo 1-fc y su utilizacion en el tratamiento de tumores
CY1110329T1 (el) Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743
BR112014024358A2 (pt) uso de iduronate-2-sulfatase por via subcutânea e kit
RU2017132324A (ru) Иммуноконъюгаты для специфической индукции цитотоксичности т-клеток против клеток-мишеней
AR057565A1 (es) Interferon alfa y c- ficocianina para el tratamiento de enfermedades auoinmunes alergicas y cancer
DE60143818D1 (de) Alpha-fetoprotein-peptide und ihre verwendung
AR022937A1 (es) Celulas mamiferas conjugadas con haptenos y metodos para su constitucion y uso
ATE458819T1 (de) Konjugat mit p21-protein zur krebsbehandlung
WO2010023195A3 (en) Compositions and methods for treating cancer
ATE484290T1 (de) Peptid mit antitumoraler wirkung
ATE552271T1 (de) Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon
AR073585A1 (es) Una proteina rica en cisteina derivada de suero en pacientes que reciben quimioterapia o radioterapia para mejorar la supervivencia de dichos pacientes. uso. metodo
CO5300468A1 (es) Antigeno asociado con tumores

Legal Events

Date Code Title Description
FG Grant, registration